Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs CarMax, Inc (KMX) Price & Performance

AbCellera Biologics IncTrade
CarMax, IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs CarMax, Inc — how do they compare? AbCellera Biologics Inc trades at $10.33 (market cap $2.99B), while CarMax, Inc trades at $58.5 (market cap $8.26B). The key difference: CarMax, Inc is far larger — about 2.8× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.

ABCLKMX
Market Cap
$2.99B$8.26B
Sector
HealthConsumer Cyclical
52-Week High
$9.76$62.17
52-Week Low
$2.78$30.88
Enterprise Value
$2.58B$26.77B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

CarMax, Inc

CarMax (KMX) trades at $58.705, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q2 2025 but beating in Q3 2025 and Q1 2026, with net income of $500.56M in 2025. Recent news includes a Zacks Strong Buy rating and a partnership with Sierra to enhance customer service, though ongoing legal investigations pose a headwind.

The stock's outlook is cautiously optimistic, supported by improving cash flow trends and analyst buy ratings, but risks include high debt levels and margin pressures. With a consensus price target of $53.09 below the current price, near-term upside may be limited despite positive momentum indicators.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About CarMax, Inc

CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.

Read more on KMX